| Next 10 |
PRVB News and Press, Provention Bio Inc.
-
Gainers: O2Micro International Limited (OIIM) +20%. Fluence Energy (FLNC) +7%. Allarity Therapeutics (ALLR) +7%. SIGA Technologies (SIGA) +6%. Blackbaud (BLKB) +5%. Losers: Redbox Entertainment (RDBX) -10%. Pacific Biosciences of California (PACB) -6%. Jamf Holding (JAMF...
-
Going against prevailing market trends can be tricky, but it can also be a rewarding strategy. Uncovering gems in the stock market that most other investors are ignoring -- or actively avoiding -- can be highly profitable in the long term. Of course, scooping up shares of beaten-down stocks...
-
Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year PR Newswire RED BANK, N.J. , May 12, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharm...
-
Provention Bio, Inc. (PRVB) Q1 2022 Earnings Conference Call May 5, 2022, 8:00 AM ET Company Participants Ashleigh Palmer – Co-Founder, President, Chief Executive Officer Francisco Leon – Co-Founder & Chief Scientific Officer Thierry Chauche – Chief Financial Officer ...
-
Provention Bio press release (NASDAQ:PRVB): Q1 GAAP EPS of -$0.35 beats by $0.11. Revenue of $0.58M misses by $0.12M. As of March 31, 2022, Provention had cash, cash equivalents and marketable securities of $113.4 million. For further details see: Provention Bio GAAP EPS of -$0.35 beats...
-
Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update PR Newswire -Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022 - -Company to host te...
-
Provention Bio (NASDAQ:PRVB) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.47 and the consensus Revenue Estimate is $0.7M. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estim...
-
Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022 PR Newswire RED BANK, N.J. , April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-media...
-
Gainers: Avadel Pharmaceuticals (AVDL) +31%. AlloVir (ALVR) +7%. Redbox Entertainment (RDBX) +6%. CymaBay Therapeutics (CBAY) +5%. Harpoon Therapeutics. (HARP) +5%. Losers: Protagonist Therapeutics (PTGX) -41%. Nkarta (NKTX) -6%. Provention Bio (PRVB...
-
On March 26th, Provention Bio announced that the FDA accepted the BLA submission of Teplizumab for the delay of type 1 diabetes (T1D) indication for at-risk individuals. The goal date for PDUFA is August 17th. Until then, there is no meaningful catalyst, meaning the stock could trade ...
Stock Information
Provention Bio Inc. Company Name:
PRVB Stock Symbol:
NASDAQ Market:
MENU
PRVB
PRVB Quote
PRVB Short
PRVB News
PRVB Articles
Get PRVB Alerts
News, Short Squeeze, Breakout and More Instantly...
-
Going against prevailing market trends can be tricky, but it can also be a rewarding strategy. Uncovering gems in the stock market that most other investors are ignoring -- or actively avoiding -- can be highly profitable in the long term. Of course, scooping up shares of beaten-down stocks...
-
Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year PR Newswire RED BANK, N.J. , May 12, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharm...
-
Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update PR Newswire -Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022 - -Company to host te...